Shanghai Conant Optical Co., Ltd. (2276.HK) Bundle
From its founding in 1996 as a leading Chinese resin spectacle lens maker to its Hong Kong Main Board debut under ticker 2276.HK on December 16, 2021, Shanghai Conant Optical has evolved through major restructurings and a 2021 joint-stock reform into a global supplier selling in over 80 countries, operating a centralized Shanghai manufacturing hub and a worldwide distribution network while focusing on innovation in smart glasses and XR headsets funded in part by a January 2025 placement that raised about HK$827 million; with 479.93 million shares outstanding as of December 31, 2024 and insiders holding roughly 44.33%, the company pairs strong internal alignment with a float of 171.06 million and an RSU grant of 11.926 million shares (≈2.8%) to drive retention and growth-financially, Conant reported 2.06 billion CNY in 2024 revenue and 539.58 million CNY net income (a 17.11% and 30.96% year-over-year rise, respectively), trades at HK$55.00 as of December 12, 2025 with a market cap of HK$26.40 billion, boasts an EPS of 1.22 and a P/E of 44.90, and maintains a low debt-to-equity ratio of 0.09, setting the stage for readers to explore how its product mix, R&D, partnerships, and diversified sales channels translate these metrics into long-term competitive positioning and shareholder value
Shanghai Conant Optical Co., Ltd. (2276.HK): Intro
History Shanghai Conant Optical Co., Ltd. (2276.HK) was founded in 1996 and established itself as a leading Chinese manufacturer of resin spectacle lenses. A major corporate restructuring began in 2018 to consolidate operations across affiliated entities (including Shanghai Conant, Jiangsu Conant and Asahi Optical) into a unified group. The restructuring progressed through joint-stock reform and was completed in 2021, after which the company completed a Hong Kong primary listing.- 1996 - Company founding; focus on resin lenses and optical materials.
- 2018 - Group-level restructuring and consolidation of operating entities.
- 2021 - Completion of joint‑stock reform; listed on the Main Board of the Hong Kong Stock Exchange (ticker: 2276) on December 16, 2021.
- January 2025 - Raised ~HK$827 million via placement of 53,325,000 new shares at HK$15.86 each to fund innovation in smart glasses and XR headsets.
- December 12, 2025 - Share price HK$55.00 (+10% from prior close); market capitalization HK$26.40 billion.
- Manufacturing: Production of resin spectacle lenses, lens blanks, and related optical components across vertically integrated facilities.
- R&D and product development: Investments in coatings, lens designs, and new form factors (progressing into smart glasses/XR modules after 2024-2025 funding).
- Sales channels: Domestic optical retailers, national optical chains, e-commerce partners, and OEM/ODM supply to international eyewear brands.
- Value chain control: Raw material sourcing, in-house lens processing, coatings, quality control and finished-lens distribution to B2B and B2C channels.
- Sale of finished prescription resin lenses (single-vision, progressive, special coatings).
- OEM/ODM manufacturing contracts for brand owners and optical chains.
- Value‑added services: anti‑reflective/mirror coatings, AR/blue‑light treatments, thin‑and‑light lens options.
- New product lines and licensing: smart glasses modules, XR headset optical subsystems funded by the January 2025 placement.
| Metric | Value / Date |
|---|---|
| Founding year | 1996 |
| Major restructuring start | 2018 |
| Joint-stock reform completed | 2021 |
| HKEX listing | December 16, 2021 (Ticker: 2276.HK) |
| January 2025 placement - proceeds | Approx. HK$827 million |
| Placement shares issued | 53,325,000 new shares |
| Placement price per share | HK$15.86 |
| Share price (12 Dec 2025) | HK$55.00 (+10% from prior close) |
| Market capitalization (12 Dec 2025) | HK$26.40 billion |
- Continued enhancement of lens materials and coatings to retain competitiveness in prescription lens markets.
- Strategic pivot into smart eyewear and XR optics using funds from the 2025 placement to develop optical modules, display coupling optics and integration capabilities.
- Partnerships and potential OEM relationships targeting consumer electronics and enterprise XR headsets.
Shanghai Conant Optical Co., Ltd. (2276.HK): History
Shanghai Conant Optical Co., Ltd. (2276.HK) was founded as an optical component manufacturer and grew into a vertically integrated supplier for eyewear frames, optical lenses, and related accessories. The company expanded capacity through both organic investment and targeted acquisitions to serve domestic and international eyewear brands. Key milestones include rapid share issuance to fund modern manufacturing lines and the introduction of employee incentive schemes to align management and shareholder interests.- Shares outstanding (Dec 31, 2024): 479.93 million (up 4.20% year-over-year)
- Insider ownership: ~44.33% (significant internal control)
- Institutional ownership: ~3.00% (modest institutional interest)
- Public float: 171.06 million shares (available for trading)
- RSU grant (announced Nov 2024): 11,926,000 restricted share units (~2.8% of issued shares), vesting 2026-2028
| Item | Value / Notes |
|---|---|
| Shares outstanding (12/31/2024) | 479.93 million |
| YOY change in shares | +4.20% |
| Insider ownership | 44.33% |
| Institutional ownership | 3.00% |
| Public float | 171.06 million shares |
| RSU award (Nov 2024) | 11,926,000 RSUs (~2.8% of issued shares) |
| RSU vesting schedule | 2026-2028 |
- Manufacturing: production of frames, lenses, and optical components using in-house facilities to control quality and margins.
- OEM/ODM sales: bulk sales to brand owners and retailers, generating recurring revenue from long-term contracts.
- Value-added services: design, finishing, and customization that command higher per-unit margins.
- Export channels: international distribution to diversify revenue and capture higher ASPs (average selling prices) abroad.
Shanghai Conant Optical Co., Ltd. (2276.HK): Ownership Structure
Shanghai Conant Optical is committed to providing high-quality resin lenses and vision solutions, emphasizing innovation and customer satisfaction. The company's stated mission - to combine science, technology, and art to create clear vision - underpins R&D, product design and customer-facing services.- Global footprint: sales in over 80 countries, including China, the United States, Japan, India, Australia, Thailand, Germany and Brazil.
- Industry standing: ranked 9th among the top 10 global resin lens manufacturers in 2020; the only company in that cohort headquartered in China.
- After-sales: dedicated support services and warranty/technical assistance to foster long-term customer relationships.
| Attribute | Detail |
|---|---|
| Ticker / Listing | 2276.HK (Hong Kong) |
| Global Reach | Sales in 80+ countries |
| 2020 Industry Rank | 9th among global resin lens manufacturers |
| Core Product Families | UV++ series, 1.74 series, single vision, progressive, hi-vex, business, specialty, anti-fog, UV shield, gaming glasses |
| Customer Focus | Standardized & customized lenses; after-sales technical support |
- Product breadth: offers both mass-market standardized lenses and high-index/customized specialty lenses to address diverse optical prescriptions and end-use cases (sports, gaming, anti-fog professional use).
- Value drivers: R&D-led product upgrades, quality control across manufacturing, global distribution network, and after-sales service that supports repeat business and brand trust.
Shanghai Conant Optical Co., Ltd. (2276.HK): Mission and Values
Shanghai Conant Optical Co., Ltd. (2276.HK) positions itself as a vertically integrated ophthalmic-optics manufacturer focused on supplying spectacle lenses and optical components to global customers while advancing lens technology and service capabilities. How It Works- Centralized manufacturing: operations based in a primary production campus in Shanghai with end-to-end control over lens fabrication, coating, inspection and packaging.
- Global distribution network: direct and partner channels serving Mainland China, the Americas, Asia, Europe, Oceania and Africa; exports span more than 60 countries and regions.
- Product mix: offers standardized prescription and plano lenses alongside customized optics (high-index, progressive, anti-reflective, blue-light, photochromic and specialty coatings).
- R&D and innovation: dedicated research teams developing improvements in lens materials, coatings and integration with smart-glasses/XR headsets to address comfort, optics and electronic integration.
- Industry collaboration: supplies spectacle lens brand owners and international ophthalmic optics companies as an OEM/ODM partner, supporting private-label and branded product lines.
- After-sales support: warranty, replacement, and technical support programs, plus quality-tracking and customer service centers to maintain product satisfaction.
| Metric | Figure / Detail |
|---|---|
| Primary manufacturing site | Shanghai centralized facility (multi-line production) |
| Approx. annual lens production capacity | ~30 million lenses/year |
| R&D staff | ~150 engineers and technicians |
| Export footprint | 60+ countries across 6 continents |
| Standard & customized SKUs | Hundreds of prescription and specialty lens variants |
| After-sales centers | Regional support hubs in APAC, EMEA and Americas |
- Product sales: primary revenue from sale of spectacle lenses (prescription, progressive, high-index), optical blanks and coated lenses to wholesalers, retailers and brand partners.
- OEM/ODM contracts: long-term manufacturing agreements and private-label production for domestic and international eyewear brands generate stable order flows.
- Value-added upgrades: higher-margin specialized lenses (progressive, photochromic, anti-reflective coatings, high-index materials) and customized geometry for premium pricing.
- R&D-driven products: new technology integration (smart glass optics, XR-compatible lens elements) targeted at emerging AR/VR and smart eyewear markets for incremental sales and licensing opportunities.
- After-sales & services: warranty repairs, lens replacement programs and technical support services that preserve customer relationships and recurring revenue.
| Indicator | Recent figure (approx.) |
|---|---|
| Reported annual revenue (most recent fiscal) | HK$1.2 billion (approx.) |
| Gross margin | ~28-32% (industry-aligned range) |
| Net profit | HK$120 million (approx.) |
| R&D spend | ~3-5% of revenue |
| Employee headcount | ~1,200-1,800 employees (global) |
- OEM/ODM relationships with international spectacle lens brands and regional optical chains strengthen recurring demand and distribution reach.
- Collaborations on XR and smart-glasses aim to capture early adopter opportunities in wearable displays and advanced optics marketplaces.
- Standardization plus customization balance allows serving mass-market channels and premium niche segments simultaneously.
Shanghai Conant Optical Co., Ltd. (2276.HK): How It Works
History, Ownership & Mission- Founded as a manufacturer of ophthalmic lenses, Shanghai Conant Optical has expanded from resin spectacle lenses into multifunctional and customized optical products.
- Listed on the Hong Kong Stock Exchange under ticker 2276.HK; corporate ownership includes institutional investors, management holdings and public float across Hong Kong and international investors.
- Mission: to deliver high-quality, technologically advanced optical solutions (standardized, multifunctional and customized lenses) and to expand into smart eyewear and XR devices through R&D and strategic partnerships.
- Primary revenue driver: sale of resin spectacle lenses to domestic and international optical retailers and distributors.
- Product mix:
- Standardized lenses (volume-driven, lower margin)
- Multifunctional lenses (e.g., anti-blue, photochromic - mid-to-high margin)
- Customized lenses (premium pricing, higher margin)
- Channels and contracts:
- Wholesale distribution to optical retailers and chains
- Direct-to-consumer sales via company e-commerce and partner platforms
- Partnerships and supply contracts with eyewear OEM/brands and healthcare institutions
- Strategic supplier and technology partnerships lower input costs for resin and coating materials and accelerate adoption of automated lens manufacturing and smart-glass modules.
- Capital raise to support new product verticals: in January 2025 Shanghai Conant Optical raised approximately HK$827 million through a share placement of 53,325,000 new shares at HK$15.86 each to fund innovation in smart glasses and XR headsets.
- Manufacturing: centralized and regional production lines for lens molding, surfacing, coating and quality control; investments in automation and optical‑grading equipment to improve per-unit margins.
- R&D: in-house optics research and external technology partnerships focused on coatings, AR/VR optics and integration of smart modules.
- Go-to-market: blended B2B (wholesale, OEM partnerships, institutional contracts) and B2C (online storefronts, co-branded retail collaborations).
| Metric | Data / Notes |
|---|---|
| Ticker | 2276.HK |
| Capital raise (Jan 2025) | HK$827,000,000 via placement |
| New shares issued (Jan 2025) | 53,325,000 shares |
| Placement price | HK$15.86 per share |
| Primary products | Resin spectacle lenses - standardized, multifunctional, customized |
| Revenue streams | Wholesale distribution, direct e-commerce sales, OEM/co-branded partnerships, institutional contracts |
| Strategic focus | Smart glasses & XR headsets R&D, manufacturing automation, supplier partnerships |
- Supplier agreements for resin and coating chemistries enhance cost stability and enable scale pricing.
- Technology collaborations with optics and electronics firms to integrate display and sensor modules into eyewear.
- Institutional and healthcare contracts broaden procurement channels (hospitals, vision screening programs, optical chains).
Shanghai Conant Optical Co., Ltd. (2276.HK): How It Makes Money
Shanghai Conant Optical generates revenue through a mix of product sales, technology licensing, and upstream-downstream integration across the eyewear and precision optics value chain. Key financial and market metrics (as of December 12, 2025) underline its commercial strength and investor expectations:- Stock price: HK$55.00 (up 10% from previous close)
- Market capitalization: HK$26.40 billion
- Trailing twelve months EPS: 1.22; P/E ratio: 44.90
- Debt-to-equity ratio: 0.09
| Year | Revenue (CNY) | Revenue Growth | Net Income (CNY) | Net Income Growth |
|---|---|---|---|---|
| 2023 | 1.76 billion | - | 412.00 million (approx.) | - |
| 2024 | 2.06 billion | +17.11% | 539.58 million | +30.96% |
- Consumer eyewear: direct-to-retail and OEM contracts for frames and lenses-high-volume, steady-margin sales.
- Precision optical components: supply to camera modules, automotive LiDAR, and industrial instruments-higher-margin B2B contracts.
- Smart glasses & XR headsets: product sales, hardware-software bundles, and potential licensing/subscription revenues for AR/VR ecosystems.
- Value-added services: after-sales, lens customization, and warranty/repair programs that boost lifetime customer value.
- Innovation focus: R&D in smart glasses and XR positions the company to capture growing AR/VR market share and recurring software or content-related revenue.
- Financial flexibility: low leverage (debt-to-equity 0.09) supports capex for manufacturing upgrades and strategic M&A to expand capabilities.
- Investor sentiment: elevated P/E (44.90) reflects market confidence in continued growth and margin expansion driven by new tech products.
Shanghai Conant Optical Co., Ltd. (2276.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.